Clinical
Weight Loss Trials of Diet Pills
Clinical Weight Loss Trials of Orlistat
(Xenical) Prescription Diet Pills
Predictive value of early weight loss in
obesity management with Orlistat
prescription diet pills: an evidence-based assessment of prescribing guidelines.
Aim
To assess the clinical usefulness of published guidelines for the use
of orlistat prescription diet pills, by studying whether weight loss of
2.5 kg or more during a 4 week dietary lead-in period, and weight losses
of 5 percent or more after 12 weeks and 10 percent or more after 6 months
of drug therapy predict weight loss and risk factor changes after 2 years.
Method
A retrospective analysis of pooled data from 2 multicentre, randomised,
placebo-controlled clinical trials with similar design. The setting for
the weight loss study was 29 centres throughout Europe. Subjects were
220 men and women (BMI 28-43 kg/m(2)) who completed 2 years of treatment.
Intervention
After a 4 week hypocaloric diet plus placebo, 2 years of treatment with
orlistat 120 mg tid, plus a hypocaloric diet for the first year and a
weight maintenance diet in year two.
Results
Weight loss 5 percent or more of body weight after 12 weeks of diet plus
orlistat therapy was a good indicator of 2 year weight loss, whereas weight
loss of 2.5 kg or more during the 4 week lead-in and 10 percent or more
after 6 months did not add significantly to the prediction of 2 year outcomes.
Patients who lost 5 percent or more of their weight at 12 weeks lost significantly
more weight after 2 years than others: -11.9 percent (95 percent confidence
interval (CI) and had significantly greater reductions in total cholesterol,
LDL-cholesterol, triglycerides, glucose, insulin, and blood pressure.
Among those who achieved 5 percent or more weight loss at 12 weeks, the
overall health benefits were not significantly greater in patients who
went on to lose 10 percent or more of body weight at 6 months compared
with those who did not achieve 10 percent or more of weight loss by month
6.
Conclusions
Of the criteria currently suggested for assessing response to orlistat
treatment, weight loss of 5 percent or more at 12 weeks accurately predicts
sustained improvements in weight and major risk factors at 2 years, while
other suggested criteria are less useful.
Source: Rissanen A, Lean M, Rossner S,
Segal KR, Sjostrom L. Obesity Research Unit, Helsinki University Central
Hospital, Helsinki, Finland.
Some Clinical Weight Loss Trials of Diet
Pills
Xenical
Diet Pills and Diabesity
Laxatives & Diet Pills
CLA Dietary Pills Trial
Orlistat Diet Pills Trial
Xenical/ Meridia Diet Pills
Xenical/ Orlistat Diet
Pills Trial
Meridia Diet Pills
Meridia & Dexfenfluramine
Sibutramine Diet Pills:
Health Trial
Meridia Diet Pills: Energy
Trial
Sibutramine Diet
Pills: Drug Abuse Trial
Sibutramine Diet Pills Trial
Sibutramine Diet Drugs:
Energy Trial
Orlistat/ Sibutramine
Diet Pills Trial
Orlistat/ Xenical Diet
Pills Trial
Dietary Supplements:
Weight Loss Trial
---------------------------------------------------------------------
|